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Abstract
Background—Vitamin D deficiency may contribute to impaired glucose metabolism. There are 
sparse data regarding vitamin D and the development of gestational diabetes (GDM). The 
objective of this study was to assess if first-trimester vitamin D deficiency is more prevalent in 
women later diagnosed with GDM compared with women with uncomplicated pregnancies.
Methods—We conducted a nested case-control study of pregnant women who had previously 
given blood for routine genetic multiple marker screening and subsequently delivered at a tertiary 
hospital between November 2004 and July 2009. From an overall cohort of 4225 women, 60 cases 
of GDM were matched by race/ethnicity with 120 women delivering at term (≥37 weeks) with 
uncomplicated pregnancies. Banked maternal serum was used to measure maternal 25-
hydroxyvitamin D [25(OH)D].
Results—The prevalence of first-trimester maternal vitamin D deficiency (defined as 25(OH)D 
<50 nmol/L) was comparable among women with GDM compared with controls (5/60 vs 8/120, p 
= 0.90). The median 25(OH)D level for all subjects was 89 nmol/L (interquartile range, 73–106 
nmol/L). Seventy three percent (117/160) of the cohort had 25(OH)D levels ≥75 nmol/L.
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Conclusions—In a cohort of pregnant women with mostly sufficient levels of serum 25(OH)D, 
vitamin D deficiency was not associated with GDM. Further studies are warranted with larger 
cohorts, especially in populations with lower levels of vitamin D.
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Introduction
Gestational diabetes mellitus is glucose intolerance that first manifests itself in pregnancy. 
This common complication of pregnancy affects approximately 4% of all births in the 
United States [1]. As the prevalence of obesity continues to increase, the rate of gestational 
diabetes is also increasing [2–4]. Women that are diagnosed with GDM are at an increased 
risk of developing diabetes mellitus later in life. Moreover, women with gestational diabetes 
are more likely to deliver macrosomic infants, which confers a higher risk for shoulder 
dystocia and birth injuries such as nerve palsies and bone fractures [5]. In addition, the 
offspring of these mothers are more likely to be obese and glucose intolerant [6,7]. 
Evaluating pathophysiologic changes associated with GDM that are amenable to therapy 
could therefore impact both neonatal and maternal outcomes.
Recent evidence suggests that vitamin D deficiency may contribute to the development of 
type 2 diabetes mellitus [8,9]. Although the exact mechanism is unknown, this relationship 
may be related to the association of vitamin D deficiency and pancreatic β-cell dysfunction 
[10]. There are sparse data regarding vitamin D and the development of GDM. Researchers 
have previously reported lower maternal 25-hydroxyvitamin D [25 (OH)D] concentrations 
in women with GDM at the time of GDM-screening (24–29-week gestation) [11,12], and a 
single study has demonstrated lower levels at 16-weeks gestation before the diagnosis of 
GDM [13]. If these findings are replicated, vitamin D supplementation in deficient women 
may aid in the prevention of GDM. Consequently, our objective was to assess if first-
trimester vitamin D deficiency is more prevalent in women with GDM. We hypothesized 
that early pregnancy levels of vitamin D are lower among women who later develop GDM 
compared with healthy women who later deliver at term.
Materials and methods
Study design
We conducted a nested case-control study in a cohort of 4225 women. All women who had 
previously given blood for routine first-trimester genetic multiple marker screening and 
subsequently delivered at the University of North Carolina-Chapel Hill, between November 
2004 and July 2009, were eligible. Nonfasting blood samples were collected for routine 
genetic multiple marker screening between 11 and 14-weeks gestation, and serum aliquots 
were barcoded and frozen at −70 °C. This study was approved by the Institutional Review 
Board at the University of North Carolina-Chapel Hill prior to data collection, and 
permission was obtained to use banked serum from these women for research purposes.
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Using a standard data collection sheet, two investigators (A. B. and S. H.) abstracted 
demographic characteristics, obstetrical and neonatal outcomes from prenatal and inpatient 
medical records. The following maternal characteristics were based on self-report: height, 
prepregnancy weight and date of last menstrual period. Gestational age was determined by 
menstrual dating. In cases of uncertain menstrual dates, ultrasound estimates of gestational 
age were used. Maternal body mass index (BMI) was calculated from the patient’s self-
reported height and prepregnancy weight. Other abstracted variables included race/ethnicity, 
maternal health insurance type and chronic maternal illness such as pregestational 
hypertension, diabetes, liver or kidney insufficiency or rheumatologic disorders.
Screening for GDM was most often performed between 24 and 28 weeks of gestation using 
a 50-gram glucose, 1-hour screening test. The threshold for obtaining a subsequent 3-hour 
100-gram oral glucose tolerance test was a serum glucose concentration of 140 mg/dL. 
National Diabetes Data Group criteria were used to establish the diagnosis of GDM [14]. 
Early screening in the first or early second trimester was performed in patients considered 
high risk for gestational diabetes (i.e. prior affected pregnancy, strong family history of type 
2 diabetes or BMI ≥30 kg/m2). If these patients were screened negative, a repeat 50-gram, 1-
hour screening test was performed between 24 and 28 weeks of gestation. Exclusion criteria 
included pre-GDM, chronic hypertension, kidney disease, known thrombophilias, multiple 
gestation, major congenital fetal anomalies or any other significant preexisting chronic 
medical disease.
From the total cohort of 4225 women, 124 women were diagnosed with GDM, and 60 had 
met all inclusion and exclusion criteria listed above. All 60 cases had an adequate volume of 
serum available for analysis. These cases were matched by race/ethnicity, in 2: 1 ratio, to a 
random computer-generated referent group of 120 healthy women delivering at term (≥37 
weeks) using the same exclusion criteria. Assuming a 25% rate of vitamin D deficiency in 
the control group, an absolute increase in vitamin D deficiency of 25% in the case group 
(50%) and α of 0.05, we needed a sample size of at least 171 patients (cases: 57, controls: 
114) to achieve 90% power.
Laboratory analyses
Serum aliquots of cases and controls were shipped on dry ice to Massachusetts General 
Hospital (MGH, Boston, MA) for serum 25(OH)D measurement by liquid chromatography–
tandem mass spectrometry [15]. The method used is an isotope dilution, liquid 
chromatography–mass spectrometry assay optimized in MGH laboratory based on published 
procedures [16]. The limit of detection is 5 nmol/L for D2 and 7.5 nmol/L for D3. Values 
that were outside the limits of detection were excluded from the analysis. The between-run 
coefficient of variation for a quality control serum containing a total vitamin D 
concentration of 57 nmol/L is 7.5%. On the basis of the definitions of vitamin D status in the 
literature [17,18], we categorized 25(OH)D ≥75 nmol/L as sufficient and 25 (OH)D 50–74.9 
nmol/L as insufficient. Vitamin D deficiency was defined as 25(OH)D <50 nmol/L.
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We performed unadjusted analyses using Wilcoxon–Mann–Whitney and Fisher’s exact tests 
to compare differences between cases and controls. Multivariable logistical regression was 
performed to evaluate independent predictors of GDM with results reported as odds ratios 
(ORs) with 95% confidence intervals (CIs). Data were analyzed using IBM SPSS Statistics 
software (version 19.0, SPSS, Inc., Chicago, IL) and were summarized using descriptive 
statistics. All p values were two-tailed, with p <0.05 considered statistically significant.
Results
We successfully analyzed 25(OH)D levels from all 180 samples (60 cases; 120 controls). 
The median gestational age of serum collection was similar for the two groups (13 weeks). 
As shown in Table 1, women with gestational diabetes had a significantly higher BMI (29 vs 
25, p = 0.003) and were delivered on average 1 week earlier than controls (38 vs 39 weeks, p 
<0.001). All other demographic and clinical characteristics between the groups in early 
pregnancy were similar. The median 25(OH)D level for all subjects was 89 nmol/L 
(interquartile range, 73–106 nmol/L). Seventy three percent (132/180) of the cohort had 
25(OH)D levels ≥75 nmol/L. There was a small negative correlation (s = −0.1) between 
BMI and 25(OH)D. There was a trend toward higher concentration of 25(OH)D in fall and 
summer and lower 25(OH)D in the winter months.
The prevalence of first-trimester maternal 25(OH)D deficiency (<50 nmol/L) was similarly 
low among women later diagnosed with GDM and healthy controls (8.3% vs 6.7%, 
respectively; p = 0.90). In unadjusted models, first-trimester maternal 25(OH)D <50 nmol/L 
was not associated with gestational diabetes (OR 1.25; 95% CI, 0.39–4.05) compared with 
first trimester levels of ≥75 nmol/L (Table 2). We similarly found no association between 
25(OH)D <50 nmol/L vs ≥75 nmol/L and gestational diabetes after adjustment for maternal 
age, insurance status, BMI, gestational age at serum collection and season of blood draw 
(adjusted OR, 0.78; 95% CI, 0.22–2.78). We also examined the mean 25(OH)D between the 
groups. While mean 25(OH)D was higher among cases (97 ± 29 vs 86 ± 22 nmol/L, p = 
0.02), this effect was attenuated by maternal BMI and season of blood draw (p = 0.24).
Discussion
In this study, we measured the association between first-trimester vitamin D deficiency and 
GDM. We found no difference in the prevalence of early pregnancy vitamin D deficiency 
(defined as 25(OH)D <50 nmol/L) between women with gestational diabetes compared with 
women with uncomplicated pregnancies delivering at term. However, the overall prevalence 
of vitamin D deficiency in our study cohort was only 7.2%, with only 13 of 180 women in 
this category. This is much lower than the recently published data reporting a 33% rate of 
vitamin D deficiency in a nationally representative sample of pregnant women in the United 
States [19].
There are few studies on vitamin D status in pregnancy and its association with gestational 
diabetes, and all of these studies reported much higher rates of vitamin D deficiency than we 
found in our cohort. Maghbooli et al. examined maternal serum 25(OH)D deficiency and 
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gestational diabetes in a cross-sectional study of 741 pregnant women at 24–28-weeks 
gestation. They reported significantly lower levels of 25(OH)D in women with gestational 
diabetes compared to euglycemic controls. In contrast to our study, the rate of severe 
vitamin D deficiency (<25 nmol/L) in the Maghbooli cohort was high at 71% [11]. Clifton-
Bligh et al. reported that maternal serum 25(OH)D concentrations at the time of glucose 
tolerance screening (29-weeks gestation) was significantly and inversely associated with 
fasting glucose. In their cohort of 307 women, 48% had a serum 25(OH)D <50 nmol/L [12]. 
In the only other study evaluating early pregnancy (16-weeks gestation) vitamin D 
deficiency and gestational diabetes, Zhang et al. noted a 2.66-fold increased risk of 
gestational diabetes in women with vitamin D deficiency. The rate of vitamin D deficiency 
(<50 nmol/L) in the Zhang study was also high at 20% [13].
Our findings must be interpreted in the context of the study design. A surprisingly high 
number of women in our cohort had sufficient vitamin D status. There are several possible 
explanations for this finding. Perhaps the most significant factor is that the majority of the 
patients in this study were privately insured (88%) and thus more likely to be taking 
nutritional supplements and be physically active [20]. Unfortunately, we do not have 
information regarding supplement use or exposure to sunlight in this study. The 
geographical location of the study (North Carolina) also could have played a role via 
unmeasured lifestyle differences (i.e. amount of time spent outside). In addition, we were 
unable to determine an optimal cutpoint for GDM, given our small sample size and small 
number of women with 25(OH)D <75 nmol/L. Although there is not uniform agreement as 
to ‘optimal’ vitamin D status, the vitamin D levels necessary to prevent rickets are much 
lower than levels that have been associated with non-bone-related outcomes [21]. Recent 
evidence suggests that vitamin D deficiency may be associated with cancer, cardiovascular 
disease, autoimmune disease and many other adverse health outcomes [22]. For examples, 
25(OH)D <75 nmol/L is associated with periodontal disease [23], and levels <50 nmol/L are 
associated with severe pre-eclampsia [24]. Moreover, our study population also may not be 
generalizable to all pregnant women. The prevalence of vitamin D deficiency in pregnancy 
is highest among African American (black) women [25]. Our study population was more 
than 50% white, which limits extrapolation to ethnically diverse groups.
Selection bias is also a concern in any case-control study, especially in the selection of 
controls. It is challenging to control for all potential covariates, and it is possible that 
unmeasured differences exist between the two study groups. However, our controls were 
nested within a large cohort of women who provided serum samples as part of routine 
prenatal screening, reducing selection bias. An important strength of our study is that 
maternal serum was collected well before the diagnosis of GDM, reducing the likelihood 
that subclinical disease affected vitamin D levels. However, it is possible that some women 
may have had prepregnancy glucose intolerance that was undiagnosed at the time blood 
draw.
In conclusion, in a cohort of women with a median serum 25(OH)D of 89 nmol/L, vitamin 
D status was not associated with GDM. Future studies in high risk, racially diverse and low 
income populations are needed to determine the association of vitamin D status and GDM.
Baker et al. Page 5














This research was supported, in part, by the Bowes/Cefalo Young Researcher Award (AMB) and the Massachusetts 
General Hospital Center for D-receptor Activation Research (CAC). The resources of the BHRC research network 
are gratefully acknowledged (A. M. B. and S. H.).
References
1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 
2008; 31(Suppl 1):S55–S60. [PubMed: 18165338] 
2. Kim C, Newton KM, Kopp RH. Gestational diabetes and the incidence of type 2 diabetes: a 
systematic review. Diabetes Care. 2002; 25:1862–1868. [PubMed: 12351492] 
3. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical 
estimates, and projections. Diabetes Care. 1998; 21:1414–1431. [PubMed: 9727886] 
4. Dabelea D, Snell-Bergeou JK, Hartsfield CL, Bischoff KJ, Hamman RF, McDuffie RS. Increasing 
prevalence of gestational diabetes mellitus (GDM) over time and by birth cohort: Kaiser 
Permanente of Colorado GDM Screening Program. Diabetes Care. 2005; 28:579–584. [PubMed: 
15735191] 
5. Langer O, Yogev Y, Most O, Xenakis EM. Gestational diabetes: the consequences of not treating. 
Am J Obstet Gynecol. 2005; 192(4):989–997. [PubMed: 15846171] 
6. Silverman BL, Metzger BE, Cho NH, Loeb CA. Impaired glucose tolerance in adolescent offspring 
of diabetic mother. Relationships to fetal hyperinsulinism. Diabetes Care. 1995; 18(5):611–617. 
[PubMed: 8585997] 
7. Petitt DJ, Bennett PH, Knowler WC, Baird HR, Aleck KA. Gestational diabetes mellitus and 
impaired glucose tolerance during pregnancy. Long-term effects on obesity and glucose tolerance in 
the offspring. Diabetes. 1985; 34(Suppl 2):119–122. [PubMed: 3996763] 
8. Forouhi NG, Luan J, Cooper A, Boucher BJ, Wareham NJ. Baseline serum 25-hydroxy vitamin D is 
predictive of future glycemic status and insulin resistance: the Medical Research Council Ely 
Prospective Study 1990–2000. Diabetes. 2008; 57(10):2619–2625. [PubMed: 18591391] 
9. Kositsawat J, Freeman VL, Gerber BS, Geraci S. Association of A1C levels with vitamin D status in 
U.S. adults: data from the National Health and Nutrition Examination Survey. Diabetes Care. 2010; 
33(6):1236–1238. [PubMed: 20215453] 
10. Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and 
beta cell dysfunction. Am J Clin Nutr. 2004; 79(5):820–825. [PubMed: 15113720] 
11. Maghbooli Z, Hossein-Nezhad A, Karimi F, Shafaei AR, Larijani B. Correlation between vitamin 
D3 deficiency and insulin resistance in pregnancy. Diabetes Metab Res Rev. 2008; 24(1):27–32. 
[PubMed: 17607661] 
12. Clifton-Bligh RJ, McElduff P, McElduff A. Maternal vitamin D deficiency, ethnicity and 
gestational diabetes. Diabet Med. 2008; 25(6):678–684. [PubMed: 18544105] 
13. Zhang C, Qui C, Hu FB, et al. Maternal plasma 25-hydroxyvitamin D concentrations and the risk 
for gestational diabetes mellitus. PLoS One. 2008; 3(11):e3753. [PubMed: 19015731] 
14. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other 
categories of glucose intolerance. Diabetes. 1979; 28(12):1039–1057. [PubMed: 510803] 
15. Roth HJ, Schmidt-Gayk H, Weber H, Niederau C. Accuracy and clinical implications of seven 25-
hydroxyvitamin D methods compared with liquid chromatography-tandem mass spectrometry as a 
reference. Ann Clin Biochem. 2008; 45:153–159. [PubMed: 18325178] 
16. Singh RJ, Taylor RL, Reddy GS, Grebe SKG. C-3 epimers can account for a significant proportion 
of total circulating 25-hydroxyvitamin D in infants, complicating accurate measurement and 
interpretation of vitamin D status. J Clin Endocrinol Metab. 2006; 91:3055–3061. [PubMed: 
16720650] 
17. Holick MF. Vitamin D deficiency. N Engl J Med. 2007; 357(3):266–281. [PubMed: 17634462] 
18. Canadian Paediatric Society. Vitamin D supplementation: recommendations for Canadian mothers 
and infants. Paediatr Child Health. 2007; 12(7):583–598. [PubMed: 19030432] 
Baker et al. Page 6













19. Ginde AA, Sullivan AF, Mansbach JM, Camargo CA Jr. Vitamin D insufficiency in pregnant and 
nonpregnant women of childbearing age in the United States. Am J Obstet Gynecol. 2010; 202(5):
436.e1–436.e8. [PubMed: 20060512] 
20. Kim J, Lee JS, Shin A, et al. Sociodemographic and lifestyle factors are associated with the use of 
dietary supplements in a Korean population. J Epidemiol. 2010; 20(3):197–203. [PubMed: 
20410671] 
21. Adams JS, Hewison M. Update in vitamin D. J Clin Endocrinol Metab. 2010; 95 (2):471–478. 
[PubMed: 20133466] 
22. Souberbielle JC, Body JJ, Lappe JM, et al. Vitamin D and musculoskeletal health, cardiovascular 
disease, autoimmunity and cancer: recommendations for clinical practice. Autoimmun Rev. 2010; 
9(11):709–715. [PubMed: 20601202] 
23. Boggess KA, Espinola JA, Moss K, Beck J, Offenbacher S, Camargo CA. Vitamin D status and 
periodontal disease among pregnant women. J Periodontol. 2010 Sep 1. epub ahead of print. 
10.1902/jop.2010.100384
24. Baker AM, Haeri S, Camargo CA Jr, Espinola JA, Stuebe AM. A nested case-control study of 
midgestation vitamin D deficiency and risk of severe preeclampsia. J Clin Endocrinol Metab. 
2010; 95 (11):5105–5109. [PubMed: 20719829] 
25. Bodnar LM, Simhan HN. Vitamin D may be a link to black-white disparities in adverse birth 
outcomes. Obstet Gynecol Surv. 2010; 65(4):273–284. [PubMed: 20403218] 
Baker et al. Page 7

























Baker et al. Page 8
Table 1
Clinical and demographic characteristics of women who developed GDM and race/ethnicity-matched women 
who did not (controls)
Variables Controls (n = 120) GDM (n = 60) p
Age (years)a 33 (30–36) 35 (31–37) 0.11
Race/ethnicity, n (%) —
 White 63 (52) 31 (52)
 Black 39 (33) 20 (33)
 Hispanic 12 (10) 6 (10)
 Other 6 (5) 3 (5)
Multiparous, n (%) 64 (53) 39 (65) 0.15
Private insurance, n (%) 105 (88) 53 (88) 0.99
Body mass indexa 25 (22–28) 29 (26–34) 0.003
Gestational age at serum collection (weeks)a 13 (12–13) 13 (12–13) 0.41
Gestational age at delivery (weeks)a 39 (39–40) 38 (37–39) <0.001
Season of blood draw, n (%) 0.002
 Winter 36 (30) 15 (25)
 Spring 26 (22) 18 (30)
 Summer 28 (23) 13 (22)
 Fall 30 (25) 14 (23)
Serum 25(OH)D level, n (%) 0.95
 <50 nmol/L 8 (6.7) 5 (8.3)
 50–74.9 nmol/L 24 (20) 11 (18.3)
 75+ nmol/L 88 (73.3) 44 (73.3)
25(OH)D, 25-hydroxyvitamin D.
a
Values are median (interquartile range).
Wilcoxon–Mann–Whitney test for continuous variables; Fisher’s exact test for categorical variables.
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